
    
      The trial consisted of 3 phases: Titration Phase, Maintenance Phase, and Follow-Up. The total
      duration of the trial was approximately 28 weeks for each individual participant, including
      the Follow-up. The participants received cebranopadol for a maximum of approximately 26
      weeks.
    
  